NASDAQ:EKSO - Ekso Bionics Stock Price, Forecast & News

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Ekso Bionics's stock reverse split before market open on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split.

Ekso Bionics Holdings Inc (NASDAQ:EKSO) posted its quarterly earnings data on Thursday, February, 27th. The company reported ($0.04) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.04). The firm earned $3.72 million during the quarter. Ekso Bionics had a negative return on equity of 376.63% and a negative net margin of 100.36%. View Ekso Bionics' Earnings History.

Ekso Bionics is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Ekso Bionics.

Ekso Bionics issued an update on its FY 2019 Pre-Market earnings guidance on Friday, January, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $13.9-13.9 million, compared to the consensus revenue estimate of $13.77 million.

3 equities research analysts have issued 12-month target prices for Ekso Bionics' shares. Their forecasts range from $1.00 to $2.90. On average, they anticipate Ekso Bionics' share price to reach $1.70 in the next twelve months. This suggests a possible upside of 466.7% from the stock's current price. View Analyst Price Targets for Ekso Bionics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ekso Bionics.

News articles about EKSO stock have trended very negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ekso Bionics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Ekso Bionics.

Some companies that are related to Ekso Bionics include CymaBay Therapeutics (CBAY), Sundial Growers (SNDL), Anpac Bio-Medical Science (ANPC), Resapp Health (RAP), Cassava Sciences (SAVA), Vaccinex (VCNX), TapImmune (MRKR), Corvus Pharmaceuticals (CRVS), Aldeyra Therapeutics (ALDX), Gamida Cell (GMDA), AcelRx Pharmaceuticals (ACRX), Medical Facilities (DR), ANGLE (AGL), IMMUTEP LTD/S (IMMP) and Electromed (ELMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include TransEnterix (TRXC), XOMA (XOMA), Infinity Augmented Reality (ALSO), Opko Health (OPK), Editas Medicine (EDIT), Innovative Industrial Properties (IIPR), NVIDIA (NVDA), Canopy Growth (CGC), Uranium Energy (UEC) and Kratos Defense & Security Solutions (KTOS).

Ekso Bionics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.15%). View Institutional Ownership Trends for Ekso Bionics.

EKSO stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Ekso Bionics.

Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EKSO stock can currently be purchased for approximately $0.30.

Ekso Bionics has a market capitalization of $26.08 million and generates $11.33 million in revenue each year. The company earns $-26,990,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Ekso Bionics employs 77 workers across the globe.View Additional Information About Ekso Bionics.

The official website for Ekso Bionics is http://www.eksobionics.com/.

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at 510-984-1761 or via email at [email protected]